Celebrex Name Keeps Drug Off Minnesota Health-System Formulary
The potential for Searle/Pfizer's arthritis therapy Celebrex to be confused with other products is keeping the drug off the formulary of Minneapolis-based Fairview Health Services, a hospital pharmacy director told a National Coalition on Health Care medical errors conference Feb. 22 in Washington, D.C.
You may also be interested in...
A decision on instituting a name change or educational campaign for Searle/Pfizer's Celebrex is expected by the end of May.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials